

For further information contact:  
Paul D'Sylva, Ph.D.  
CEO  
Commonwealth Biotechnologies, Inc.  
858 550 0959 ext. 106

**Tripes Discovery Research, Ltd., a subsidiary of Commonwealth Biotechnologies, Inc., signs Library Analysis Agreement with Elan Pharmaceuticals, Inc.**

Richmond, VA, and Bude, England (August 09, 2007) Tripes Discovery Research Limited (TDR), a wholly owned subsidiary within the Commonwealth Biotechnologies, Inc. (CBI) group of companies (NASDAQ Capital Market: CBTE) announced today that it has entered into a Master Service Agreement with Elan Pharmaceuticals, Inc. to assist in analyzing and enhancing the diversity of its corporate small molecule screening collection.

Under the terms of the agreement, TDR shall provide its computational design expertise to perform an analysis on the Elan screening collection of small molecule compounds to perform computational clustering of key subsets and determine optimal areas for expansion. Additionally, TDR shall provide high throughput quality control analyses of legacy compounds via mass spectrometry.

Commenting on the agreement, Paul D'Sylva CEO of CBI, stated "This announcement is evidence of another leading pharmaceutical company demonstrating its confidence in TDR and the global reach of our services and products. TDR has been providing world-class computational analysis, design expertise and compound screening enhancement services to many leading pharmaceutical companies over the past ten years. Corporate small molecule collections are key assets for pharmaceutical companies, and Elan's investment in this project is testimony to its desire to ensure that it has an optimal collection to maximize its return from screening of disease targets and minimize time-wasting false positives. We are privileged to be working with Elan."

**About Tripes Discovery Research Limited**

Tripes Discovery Research Ltd (TDR) is a leading knowledge driven, drug discovery services business that provides pharmaceutical and biotechnology companies with novel approaches to drug discovery. Applying proprietary computational design and therapeutic medicinal chemistry tools and expertise, TDR believes that it is able to reduce drug discovery timelines by up to 30%. Since 1997, TDR has been offering compound libraries under the LeadQuest® brand, screening libraries under the LeadScreen® brand and custom de novo compound libraries under the LeadSelect® brand.

**About Commonwealth Biotechnologies, Inc**

The CBI group offers cutting-edge R&D products and services to the global life sciences industry. CBI now operates four distinct business units: (1) CBI Services, a discovery phase contract research organization with a major emphasis in biodefense contracting; (2) Fairfax Identity Laboratories, a DNA reference business; (3) Mimotopes Pty, Ltd., Melbourne, Australia, a peptide and discovery chemistry business; and (4) Tripos Discovery Research, Ltd., Bude, UK, a medicinal and synthetic discovery chemistry business. Collectively, CBI companies employ over 140 staff in world-class laboratories. For more information, visit CBI on the web at [www.cbi-biotech.com](http://www.cbi-biotech.com)

### **Forward Looking Statements**

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, including statements regarding CBI's expectations, beliefs, intentions or strategies regarding the future. Forward-looking statements include, but are not limited to, express or implied statements regarding future revenues and/or profits generated by CBI from the Elan Master Service Agreement. CBI cannot guaranty that it will generate revenues or profits from the Elan Master Service Agreement. All forward-looking statements included in this press release are based upon information available to CBI as of the date hereof. CBI assumes no obligation to update any such forward-looking statements. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially from those projected. These and other risks relating to CBI's business are set forth in CBI's Form 10-KSB filed with the Securities and Exchange Commission on March 30, 2007, and CBI's Form 10-QSBs and other reports filed from time to time with the Securities and Exchange Commission.